First Midwest Bank Trust Division increased its stake in Allergan PLC. (NYSE:AGN) by 18.7% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 22,722 shares of the company’s stock after buying an additional 3,580 shares during the period. Allergan PLC. accounts for approximately 0.7% of First Midwest Bank Trust Division’s holdings, making the stock its 29th largest position. First Midwest Bank Trust Division’s holdings in Allergan PLC. were worth $5,524,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. BKD Wealth Advisors LLC bought a new stake in shares of Allergan PLC. during the first quarter valued at about $219,000. American National Bank boosted its stake in shares of Allergan PLC. by 0.6% in the first quarter. American National Bank now owns 15,233 shares of the company’s stock valued at $3,640,000 after buying an additional 95 shares in the last quarter. Atria Investments LLC boosted its stake in shares of Allergan PLC. by 35.1% in the first quarter. Atria Investments LLC now owns 7,310 shares of the company’s stock valued at $1,747,000 after buying an additional 1,900 shares in the last quarter. Cribstone Capital Management LLC boosted its stake in shares of Allergan PLC. by 3.6% in the first quarter. Cribstone Capital Management LLC now owns 6,803 shares of the company’s stock valued at $1,625,000 after buying an additional 236 shares in the last quarter. Finally, Graybill Bartz & Assoc Ltd. boosted its stake in shares of Allergan PLC. by 1.5% in the first quarter. Graybill Bartz & Assoc Ltd. now owns 17,635 shares of the company’s stock valued at $4,213,000 after buying an additional 255 shares in the last quarter. Institutional investors own 84.77% of the company’s stock.

Allergan PLC. (NYSE:AGN) traded up 0.29% during trading on Friday, hitting $232.88. 1,820,899 shares of the company were exchanged. The stock’s 50-day moving average is $245.93 and its 200-day moving average is $238.13. Allergan PLC. has a 12 month low of $184.50 and a 12 month high of $256.80. The company has a market capitalization of $77.85 billion, a price-to-earnings ratio of 7.10 and a beta of 1.16.

Allergan PLC. (NYSE:AGN) last announced its earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.95 by $0.07. The company had revenue of $4.01 billion during the quarter, compared to analyst estimates of $3.95 billion. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. Allergan PLC.’s revenue was up 8.8% compared to the same quarter last year. During the same quarter last year, the firm posted $3.35 earnings per share. Equities research analysts anticipate that Allergan PLC. will post $16.27 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 15th. Stockholders of record on Friday, August 18th will be paid a $0.70 dividend. This represents a $2.80 annualized dividend and a dividend yield of 1.20%. The ex-dividend date is Wednesday, August 16th. Allergan PLC.’s payout ratio is 9.95%.

TRADEMARK VIOLATION WARNING: “First Midwest Bank Trust Division Raises Stake in Allergan PLC. (NYSE:AGN)” was originally reported by Daily Political and is owned by of Daily Political. If you are viewing this article on another publication, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this article can be viewed at https://www.dailypolitical.com/2017/08/13/first-midwest-bank-trust-division-raises-stake-in-allergan-plc-nyseagn.html.

Several equities research analysts recently issued reports on AGN shares. Citigroup Inc. restated a “focus list” rating and issued a $261.27 target price (up previously from $184.50) on shares of Allergan PLC. in a report on Friday, April 21st. Royal Bank Of Canada raised their target price on shares of Allergan PLC. from $279.00 to $284.00 and gave the stock an “outperform” rating in a report on Wednesday, May 10th. Goldman Sachs Group, Inc. (The) cut shares of Allergan PLC. from a “buy” rating to a “neutral” rating and set a $262.00 target price on the stock. in a report on Wednesday, May 10th. UBS AG reiterated a “buy” rating and issued a $275.00 price target on shares of Allergan PLC. in a research report on Monday, May 15th. Finally, Sanford C. Bernstein reiterated an “outperform” rating on shares of Allergan PLC. in a research report on Thursday, May 25th. Eight analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $274.49.

In other news, Director Nesli Basgoz sold 1,889 shares of the firm’s stock in a transaction that occurred on Thursday, May 18th. The shares were sold at an average price of $220.45, for a total value of $416,430.05. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.36% of the company’s stock.

About Allergan PLC.

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.